The OJC Episode 7: ASCO Special Episode Part 2

CJ

1. Christian U. Blank et al. Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial. J Clin Oncol 42, 2024 (suppl 17; abstr LBA2). Access online here.
2. Caroline Robert et al. Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced BRAF-V600E/K-mutated melanoma: The primary analysis of an EORTC randomized phase II study (EBIN). J Clin Oncol 42, 2024 (suppl 17; abstr LBA9503). Access online here.
3. Axel Hauschild et al. Long-term follow up for adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma: Final results of the COMBI-AD study. J Clin Oncol 42, 2024 (suppl 16; abstr 9500). Access online here.
4. Jennifer Rachel Eads, et al. A phase II/III study of peri-operative nivolumab (nivo) and ipilimumab (ipi) in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: Results of the neoadjuvant pathologic complete response (pCR) rate (ECOG-ACRIN EA2174). J Clin Oncol 42, 2024 (suppl 16; abstr 4000) Access online here.
5. Salah-Eddin Al-Batran et al. Effect of chemotherapy/targeted therapy alone vs. chemotherapy/targeted therapy followed by radical surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction: The IKF-575/RENAISSANCE phase III trial. J Clin Oncol 42, 2024 (suppl 17; abstr LBA4001). Access online here.
6. Filippo Pietrantonio et al. Ramucirumab plus paclitaxel as switch maintenance versus continuation of oxaliplatin-based chemotherapy in patients (pts) with advanced HER2-negative gastric or gastroesophageal junction (GEJ) cancer: The ARMANI phase III trial. J Clin Oncol 42, 2024 (suppl 17; abstr LBA4002). Access online here.
7. Efrat Dotan et al. A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer (GIANT): ECOG-ACRIN EA2186. J Clin Oncol 42, 2024 (suppl 16; abstr 4003). Access online here.
8. Ross A. Abrams. NRG Oncology/RTOG 0848: Results after adjuvant chemotherapy +/- chemoradiation for patients with resected periampullary pancreatic adenocarcinoma (PA). J Clin Oncol 42, 2024 (suppl 16; abstr 4005) Access online here.
9. Maria A. Hawkins et al. Addition of stereotactic body radiotherapy (SBRT) to systemic chemotherapy in locally advanced cholangiocarcinoma (CC) (ABC-07): Results from a randomized phase II trial. J Clin Oncol 42, 2024 (suppl 16; abstr 4006) Access online here.

Kate:

1. Pier Franco Conte et al. A-BRAVE trial: A phase III randomized trial with avelumab in early triple-negative breast cancer with residual disease after neoadjuvant chemotherapy or at high risk after primary surgery and adjuvant chemotherapy. J Clin Oncol 42, 2024 (suppl 17; abstr LBA500). Access online here.

Craig:

1. Joseph A. Greer et al. Comparative effectiveness trial of early palliative care delivered via telehealth versus in person among patients with advanced lung cancer. J Clin Oncol 42, 2024 (suppl 17; abstr LBA3). Access online here.
2. Jennifer S. Temel et al. Multi-site randomized trial of stepped palliative care (PC) for patients with advanced lung cancer. J Clin Oncol 42, 2024 (suppl 16; abstr 12000). Access online here.
3. Benjamin J. Solomon et al. Lorlatinib vs crizotinib in treatment-naïve patients with advanced ALK+ non-small cell lung cancer: 5-year progression-free survival and safety from the CROWN study. J Clin Oncol 42, 2024 (suppl 17; abstr LBA8503). Access online here.
4. Suresh S. Ramalingam et al. Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Primary results of the phase 3 LAURA study. J Clin Oncol 42, 2024 (suppl 17; abstr LBA4). Access online here.
5. David R. Spigel et al. ADRIATIC: Durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC). J Clin Oncol 42, 2024 (suppl 17; abstr LBA5) Access online here.
6. Luis G. Paz-Ares et al. Sacituzumab govitecan (SG) vs docetaxel (doc) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) previously treated with platinum (PT)-based chemotherapy (chemo) and PD(L)-1inhibitors (IO): Primary results from the phase 3 EVOKE-01 study. J Clin Oncol 42, 2024 (suppl 17; abstr LBA8500). Access online here.
7. Mitchell S. von Itzstein et al. Phase 1/2 trial of the XPO1 inhibitor selinexor in combination with docetaxel in previously treated, advanced KRAS mutant non-small cell lung cancer (NSCLC). J Clin Oncol 42, 2024 (suppl 16; abstr 8597). Access online here.

HOSTS:

Craig Underhill

Professor Craig Underhill

Professor Craig Underhill completed his Bachelor of Medicine and Surgery in 1987 at Melbourne University. He completed medical oncology training in Melbourne and worked as the Senior Clinical Research Registrar at Guy’s Hospital, London.

In 1998 arrived in Albury-Wodonga and established a medical oncology practice and clinical trials unit which has developed expertise and infrastructure to ensure the initiation of high quality trials. The research Unit lead by Dr Underhill has twice been awarded NSW Premier’s Award for Innovation in Cancer Clinical Trials, the inaugural award in 2009 and then again in 2012.

Dr Underhill is the VCCC Regional Oncology Lead and advocates for the increased access to clinical trials for regional Victorians and leads the VCCC teletrials program.

You can find Craig on X/Twitter here: @CraigUnderhill

Kate Clarke

Dr. Kate Clarke

Dr Kate Clarke (MBChB (Otago), FRACP) is a proud New Zealander with a real love for beautiful Aotearoa. Dr Clarke continues to work at being Tangata Tiriti. Much of her research and patient advocacy has an equity focus.  Dr Clarke is grateful to her patients, students, whanau and colleagues for the knowledge and awhi they share.  Ehara taku toa, he takitahi, he toa takitini.

Dr Clarke completed her medical training in Otago, Wellington and London. She has a holistic approach and is passionate about patient-centred care, and believes patients can and should play an active role in their healthcare. Her clinical experience covers a broad range of solid tumour malignancies with special clinical interest in colorectal cancer, upper gastrointestinal cancers and breast cancer.

Chris ‘CJ’ Jackson

Professor Christopher Jackson

Chris Jackson is Professor of Medical Oncology at the University of Otago, Dunedin, and a medical oncologist at Dunedin Hospital and Mercy Cancer Care. He specialises in GI cancers and melanoma, teaches medical students and specialists-in-training, and is heavily involved in both national and international cancer policy, leadership and research.

He was previously the medical director of the Cancer Society of NZ, and his advocacy led to the funding of new cancer drugs, to the development of a new national cancer plan, and to the birth of the national cancer agency Te Aho o Te Kahu.  He currently chairs the agency’s clinical committee and serves on the advisory board. In addition, he is on the programme board of the International Cancer Benchmarking Project, and is a founding member of the Common Sense Oncology movement.

Chris is a self-confessed Radiohead tragic, and recent convert to Crossfit (even though you didn’t ask).

Connect with CJ on X/Twitter: @drkiwicj

PRODUCER:

Rachael Babin

Rachael Babin is Host of The Oncology Podcast, Editor-in-Chief of The Oncology Newsletter,  and Publisher of Oncology News Australia and The Oncology Network.

With a background in oncology communications and academic publishing, Rachael is happiest sitting behind the mic chatting to interesting people about the impact their work makes in oncology.

Connect on Twitter: @OncologyNewsAus